AS
ASND.US Ascendis Pharma AS
- Market cap
- USD 18.2B
- P/E
- 18.2x
- P/B
- 10.44x
- ROE
- 80.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ASND.US undervalued?
Graham numberASND.US trades 190.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ascendis Pharma AS fundamental analysis
No fundamental analysis for Ascendis Pharma AS yet.
Ascendis Pharma AS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease produc…
Full company profileAscendis Pharma AS financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Ascendis Pharma AS annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.61M | 1.53M | 10.6M | 13.4M | 6.95M | 7.78M | 51.2M | 267M | 364M | 692M | 1.28B |
| Gross Profit | 4.61M | 1.53M | 10.6M | 13.4M | 6.95M | 4.26M | 39.0M | 222M | 319M | 589M | 1.17B |
| Operating Income | -72.9M | -112M | -155M | -227M | -331M | -452M | -562M | -456M | -279M | -131M | 283M |
| EBITDA | -68.1M | -124M | -129M | -210M | -408M | -365M | -529M | -411M | -290M | -110M | 294M |
| Net Income | -68.5M | -124M | -130M | -218M | -419M | -384M | -583M | -481M | -378M | -219M | 1.23B |
| EPS | -2.58 | -3.68 | -3.17 | -4.69 | -8.28 | -7.00 | -10 | -8.55 | -6.53 | -3.61 | 18 |
| Balance Sheet | |||||||||||
| Total Assets | 190M | 211M | 319M | 677M | 980M | 1.08B | 1.09B | 826M | 1.18B | 1.30B | 2.47B |
| Total Liabilities | 13.5M | 23.8M | 38.9M | 79.6M | 141M | 201M | 826M | 971M | 1.29B | 1.46B | 942M |
| Shareholders' Equity | 177M | 187M | 280M | 597M | 839M | 884M | 263M | -146M | -106M | -163M | 1.53B |
| Cash & Short-term Investments | 180M | 195M | 278M | 598M | 719M | 682M | 735M | 399M | 560M | 616M | 981M |
| Total Debt | 0.00 | 0.00 | 0.00 | 36.6M | 92.0M | 210M | 618M | 743M | 857M | 871M | 455M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -60.2M | -95.1M | -139M | -176M | -272M | -418M | -496M | -467M | -306M | 51.8M | 618M |
| Capital Expenditure | 672K | 941K | 2.65M | 5.16M | 21.6M | 24.2M | 14.5M | 2.44M | 1.43M | 8.15M | 18.3M |
| Free Cash Flow | -60.9M | -96.0M | -141M | -181M | -293M | -442M | -510M | -470M | -308M | 43.6M | 599M |
| Ratios | |||||||||||
| ROE | -38.8% | -66.2% | -46.5% | -36.5% | -50.0% | -43.4% | -221.5% | - | - | - | 80.7% |
| ROA | -36.0% | -58.7% | -40.8% | -32.2% | -42.8% | -35.4% | -53.5% | -58.3% | -32.1% | -16.8% | 49.9% |
| Net Profit Margin | -1,487.3% | -8,097.8% | -1,229.5% | -1,630.0% | -6,025.5% | -4,931.6% | -1,139.6% | -180.5% | -104.0% | -31.7% | 95.9% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.06x | 0.11x | 0.24x | 2.35x | - | - | - | 0.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ascendis Pharma AS dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | EUR 5.06M | 0.09 | - |
| 2021 | EUR 33.1M | 0.61 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Ascendis Pharma AS
- Insiders 0.79%
- Institutions 99.21%
- Public & others 0.00%
- Shares outstanding 65.6M
- Free float 65.4M
Top funds holding ASND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Janus Henderson Hrzn Biotec E2 USD | 228K | 0.35% | 0.00% | Mar 2026 |
| Spyglass US Growth F USD Inc | 69.3K | 0.11% | -0.91% | Mar 2026 |
| Invesco NASDAQ Next Gen 100 ETF | 29.9K | 0.05% | +0.48% | Apr 2026 |
| Russell Inv Tax-Managed US Mid&Sm Cap S | 15.6K | 0.02% | 0.00% | Sep 2026 |
| First Trust Long/Short Equity ETF | 15.5K | 0.02% | 0.00% | Apr 2026 |
| Rhenman Healthcare Equity L/S RC2 SEK | 15.0K | 0.02% | 0.00% | Jan 2026 |
| American Century US Fcs Innovt Eq S USD | 14.1K | 0.02% | +0.04% | Mar 2026 |
| First Trust Innovation Leaders ETF | 13.8K | 0.02% | 0.00% | Apr 2026 |
| Nomura VIP Global Growth Service | 11.9K | 0.02% | -1.26% | Mar 2026 |
| Hussman Strategic Market Cycle Fund | 8.00K | 0.01% | 0.00% | Mar 2026 |
| Invesco Global Small Cap Equity Pool I | 7.22K | 0.01% | 0.00% | Mar 2026 |
| AdvisorShares Dorsey Wright ADR ETF | 5.59K | 0.01% | 0.00% | Apr 2026 |
| Steadyhand Global Small-Cap Equity | 5.40K | 0.01% | 0.00% | Jun 2026 |
| Fidelity NorthStar Sr F | 5.40K | 0.01% | 0.00% | Mar 2026 |
| Russell Inv US Small Cap Equity Y | 4.69K | 0.01% | 0.00% | Sep 2026 |
| Virtus Biotech ETF | 4.13K | 0.01% | 0.00% | Apr 2026 |
| Invesco Nasdaq Biotechnology ETF | 3.27K | 0.01% | -0.34% | Apr 2026 |
| Evolutionary Tree Innovators I | 2.99K | 0.00% | -4.54% | Feb 2026 |
| Voya Russell Mid Cap Index Port I | 2.97K | 0.00% | +6.87% | Sep 2026 |
| PPS Global Equity B USD Acc | 2.40K | 0.00% | -12.91% | Mar 2026 |
Top institutions holding ASND.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 225K | 0.34% | +68.87% | Jun 2026 |
| Neuberger Berman Group LLC | 143K | 0.22% | 0.00% | Jun 2026 |
| ODDO BHF Asset Management SAS | 129K | 0.20% | 0.00% | Jun 2026 |
| Quadrature Capital Limited | 40.8K | 0.06% | 0.00% | Jun 2026 |
| Ferguson Wellman Capital Management, Inc | 2.60K | 0.00% | 0.00% | Jun 2026 |
| Dearborn Partners LLC | 2.60K | 0.00% | +100.00% | Jun 2026 |
| E Fund Management (HK) Co., Ltd | 84.00 | 0.00% | +40.00% | Jun 2026 |
| Ninepoint Partners LP | 26.00 | 0.00% | -99.52% | Jun 2026 |
| IFP Advisors, LLC | 14.00 | 0.00% | +16.67% | Jun 2026 |
| Huntington National Bank | 1.00 | 0.00% | 0.00% | Jun 2026 |
| Affinity Asset Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| AllianceBernstein L.P. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Allianz Asset Management AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| AlphaCentric Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Ancora Advisors LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Amvescap Plc. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Atika Capital Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisors Asset Management | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Artisan Partners Limited Partnership | 0.00 | 0.00% | -100.00% | Jun 2026 |
Ascendis Pharma AS company profile
- Company name
- Ascendis Pharma AS
- Ticker
- ASND.US
- ISIN
- DK0060615755
- Exchange
- USA Stocks
- Listed since
- Jan 28, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,189
- Fiscal year end
- December
- Address
- Tuborg Boulevard 12, Hellerup, Denmark, 2900
- Phone
- 45 70 22 22 44
- Website
- ascendispharma.com
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Ascendis Pharma AS management
10- Mr. Jan Moller MikkelsenPresident, CEO, Member of Executive Board & Executive Director · born 1960
- Mr. Scott T. SmithCFO, Executive VP & Member of Executive Board · born 1974
- Ms. Pedersen Anni Lotte Kirstine SonderbjergExecutive VP, Chief Administrative Officer & Member of the Executive Board · born 1961
- Mr. Michael Wolff Jensen L.L.M.Executive VP, Chief Legal Officer & Member of the Executive Board · born 1971
- Mr. Mads BodenhoffSenior VP, Head of Finance & Principal Accounting Officer · born 1970
- Mr. Chad FugureVice President of Investor Relations
- Mr. Flemming Steen JensenExecutive Vice President of Product Supply & Quality · born 1961
- Dr. Kennett Sprogoe Ph.D.Executive VP and Head of Research & Product Development · born 1979
- Mr. Joseph KellyHead of U.S. Commercial of Endocrinology · born 1969
- Mr. Jay Donovan WuExecutive VP & President of Ascendis US · born 1985